Singapore, September 24, 2024 – Update on the Detection of the latest SARS-CoV-2 Variant
Credo Diagnostics Biomedical Pte. Ltd. is committed to the post-market monitoring of the
reliability of our assays. We have performed nucleotide analysis using the BLASTn method
comparing primers and probes of the assays involving SARS-CoV-2 virus detection to all
sequences listed in NCBI Virus and GISAID up till September 24th, 2024.
We are pleased to announce that the VitaPCR™ system can detect the concerned SARS-CoV-2
variants and lineages as listed in the table below.
Our analysis has confirmed that the performance of our SARS-Cov-2 detection assays* are not
impacted by the variants.
*The SARS-CoV-2 RNA detection assays include:
- VitaPCR™ Influenza/SARS-CoV-2 (Flu/SC2) Assay (PCRAE0128)
- VitaPCR™ SARS-CoV-2 Assay (PCRAE0114)
- VitaPCR™ SARS-CoV-2 Gen 2 Assay (PCRAE0120)
For more information, contact us at service@credodxbiomed.com.
